Access to anti-retroviral drugs, male in Peru

Peru: Access to anti-retroviral drugs, male was 79.0% in 2024. ◆ Volatile

Latest (2024)
79.0%
Change on year
up 5.3%
World rank
49th
of 141 countries
All-time high
79.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Peru, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 1 %2003: 3 %2004: 2 %2005: 5 %2006: 8 %2007: 11 %2008: 13 %2009: 19 %2010: 27 %2011: 28 %2012: 35 %2013: 35 %2014: 39 %2015: 38 %2016: 48 %2017: 53 %2018: 60 %2019: 68 %2020: 69 %2021: 73 %2022: 76 %2023: 75 %2024: 79 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Peru stood at 79.0%. That is the highest value across all 25 years on record.

The figure is up 5.3% on the previous year and up 102.6% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Peru peaked at 79.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Peru 49th out of 141 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Peru, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Peru, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 1.0%
2003 3.0% +200.0%
2004 2.0% -33.3%
2005 5.0% +150.0%
2006 8.0% +60.0%
2007 11.0% +37.5%
2008 13.0% +18.2%
2009 19.0% +46.2%
2010 27.0% +42.1%
2011 28.0% +3.7%
2012 35.0% +25.0%
2013 35.0% +0.0%
2014 39.0% +11.4%
2015 38.0% -2.6%
2016 48.0% +26.3%
2017 53.0% +10.4%
2018 60.0% +13.2%
2019 68.0% +13.3%
2020 69.0% +1.5%
2021 73.0% +5.8%
2022 76.0% +4.1%
2023 75.0% -1.3%
2024 79.0% +5.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 6.2% 0.0% 19.0% 10
2010s 43.1% 27.0% 68.0% 10
2020s 74.4% 69.0% 79.0% 5

Countries ranked near Peru

  1. 46 Uganda 81.0% compare
  2. 47 Azerbaijan 80.0% compare
  3. 47 Lebanon 80.0% compare
  4. 49 Cameroon 79.0% compare
  5. 51 Benin 78.0% compare
  6. 51 Canada 78.0% compare
  7. 51 El Salvador 78.0% compare

See the full ranking of 160 places →

More gender data for Peru

All data for Peru →

Frequently asked questions

What is access to anti-retroviral drugs, male in Peru?
Access to anti-retroviral drugs, male in Peru was 79.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Peru?
The highest recorded value was 79.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Peru?
The lowest recorded value was 0.0% in 2000.
How does Peru rank for access to anti-retroviral drugs, male?
Peru ranks 49th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Peru?
Over the last ten years it is up 102.6%. The long-run trend across the full record is volatile.
Where does this Peru data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Peru. Statizoid, drawing on UNAIDS estimates. Retrieved 06 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/peru/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/peru/">Access to anti-retroviral drugs, male in Peru</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.